A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

NCT06400472
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
495
clinicaltrials.gov
Lead sponsor
Eli Lilly and Company
clinicaltrials.gov
Start date
2024-05-20
clinicaltrials.gov
Number of sites
23
clinicaltrials.gov

Summary
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
clinicaltrials.gov
Short title
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
clinicaltrials.gov
Official title
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
clinicaltrials.gov

Control arm
Open label
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2027-04-01
clinicaltrials.gov
First posted
2024-05-06
clinicaltrials.gov
Registry last updated
2026-06-18
clinicaltrials.gov
Primary completion date
2027-02-01
clinicaltrials.gov
Start date
2024-05-20
clinicaltrials.gov

Participants
495
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
495
clinicaltrials.gov
Protocol amendments
6
clinicaltrials.gov
Number of sites
23
clinicaltrials.gov

Data monitoring committee
Yes
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Eli Lilly and Company
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT06400472
clinicaltrials.gov
ClinicalTrials.gov ID
NCT06400472
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
No masking
Sources for study design
clinicaltrials.gov

  1. Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156

    Timeframe: 1 Cycle (21 days)

    Number of participants with dose-limiting toxicities (DLTs)

  2. Phase 1a: To determine the RP2D or optimal dose of LY4170156 with bevacizumab

    Timeframe: 1 Cycle (21 days)

    Number of participants with DLTs

  3. Phase 1a: To determine the RP2D or optimal dose of LY4170156 with carboplatin

    Timeframe: 1 Cycle (21 days)

    Number of participants with DLTs

  4. Phase 1a: To determine the RP2D or optimal dose of LY4170156 with pembrolizumab

    Timeframe: 1 Cycle (21 days)

    Number of participants with DLTs

  5. Phase 1b: To assess the antitumor activity of LY4170156 Monotherapy: Overall response rate (ORR)

    Timeframe: Up to Approximately 48 Months or 4 Years

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  6. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Timeframe: Up to Approximately 48 Months or 4 Years

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

  1. To characterize the pharmacokinetics (PK) properties of LY4170156: Minimum Plasma Concentration (Cmin)

    Timeframe: First 4 Cycles (84 days)

    PK: Cmin of LY4170156

  2. To characterize the PK properties of LY4170156: Cmin with bevacizumab or carboplatin

    Timeframe: First 4 Cycles (Approximately 84 days)

    PK: Cmin of LY4170156

  3. To characterize the PK properties of LY4170156: Cmin with pembrolizumab

    Timeframe: First 4 Cycles (84 days)

    PK: Cmin of LY4170156

  4. To characterize the PK properties of LY4170156: Area under the concentration versus time curve (AUC)

    Timeframe: First 4 Cycles (84 days)

    PK: AUC of LY4170156

  5. To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR)

    Timeframe: Up to Approximately 48 Months or 4 Years

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  6. To evaluate the preliminary antitumor activity of LY4170156: Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab

    Timeframe: Up to Approximately 48 Months or 4 Years

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

  7. To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR)

    Timeframe: Up to Approximately 48 Months or 4 Years

    DOR per investigator assessed RECIST 1.1

  8. To evaluate the preliminary antitumor activity of LY4170156: Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab

    Timeframe: Up to Approximately 48 Months or 4 Years

    DOR per investigator assessed RECIST 1.1

  9. To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR)

    Timeframe: Up to Approximately 48 Months or 4 Years

    TTR per investigator assessed RECIST 1.1

  10. To evaluate the preliminary antitumor activity of LY4170156: Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab

    Timeframe: Up to Approximately 48 Months or 4 Years

    TTR per investigator assessed RECIST 1.1

  11. To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS)

    Timeframe: Up to Approximately 48 Months or 4 Years

    PFS per investigator assessed RECIST 1.1

  12. To evaluate the preliminary antitumor activity of LY4170156: Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab

    Timeframe: Up to Approximately 48 Months or 4 Years]

    PFS per investigator assessed RECIST 1.1

  13. To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR)

    Timeframe: Up to Approximately 48 Months or 4 Years

    DCR per investigator assessed RECIST 1.1

  14. To evaluate the preliminary antitumor activity of LY4170156: Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab

    Timeframe: Up to Approximately 48 Months or 4 Years

    DCR per investigator assessed RECIST 1.1

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Healthy volunteers
No

  • Have one of the following solid tumor cancers:

    • Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
    • Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
    • Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, and TNBC

  • Individual with known or suspected uncontrolled central nervous system (CNS) metastases
  • Individual with history of carcinomatous meningitis
  • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Individual with evidence of corneal keratopathy or history of corneal transplant
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  • History of pneumonitis/interstitial lung disease
  • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Sources for eligibility
clinicaltrials.gov

  • HonorHealthScottsdale, United StatesRecruiting
  • University of California, San Diego (UCSD) - Moores Cancer CenterLa Jolla, United StatesRecruiting
  • South Texas Accelerated Research Therapeutics (START) MidwestGrand Rapids, United StatesRecruiting
  • NYU Langone Health - Long IslandMineola, United StatesRecruiting
  • New York University (NYU) Clinical Cancer CenterNew York, United StatesRecruiting
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew York, United StatesRecruiting
  • The Ohio State University (OSU) Wexner Medical CenterColumbus, United StatesRecruiting
  • The University of Texas - MD Anderson Cancer CenterHouston, United StatesRecruiting
  • START Mountain RegionWest Valley City, United StatesRecruiting
  • Cancer Research SAAdelaide, AustraliaRecruiting
  • Icon Cancer Centre South BrisbaneQLD, AustraliaRecruiting
  • Centre Leon BerardLyon, FranceRecruiting
  • Institut de Cancerologie de l'Ouest - site St-HerblainSaint-Herblain, FranceRecruiting
  • Oncopole Claudius RegaudToulouse, FranceRecruiting
  • Humanitas San Pio XMilan, ItalyRecruiting
  • Istituto Europeo di OncologiaMilan, ItalyRecruiting
  • Shizuoka Cancer CenterShizuoka, JapanRecruiting
  • National Cancer Center HospitalTokyo, JapanRecruiting
  • Cancer Institute Hospital of JFCRTokyo, JapanRecruiting
  • National Cancer CenterGoyang-si Gyeonggi-do, South KoreaRecruiting
  • Hospital Universitario Vall d'HebronBarcelona, SpainRecruiting
  • Hospital Universitario 12 de OctubreMadrid, SpainRecruiting
  • Hospital Clinico Universitario de ValenciaValencia, SpainRecruiting
Sources for sites
clinicaltrials.gov

  • 2024-511238-11-00
  • J5E-OX-JZXA
Sources for references
clinicaltrials.gov

Related records

Drugs (4)

Lead sponsors (1)

Conditions (9)

Targets (2)